The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors
"Rare cancers" are a diverse collection of cancers that collectively account for approximately 20% of all adult cancers in the United States. Their rarity has caused an underrepresentation of these cancers in preclinical research and clinical trials, leading to fewer (and often no) treatme...
Saved in:
Main Authors: | Arjun Mittra (Author), Naoko Takebe (Author), Vaia Florou (Author), Alice P Chen (Author), Abdul Rafeh Naqash (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
by: Emer Lynch, et al.
Published: (2023) -
Advances in immune checkpoint inhibitors for hepatocellular carcinoma
by: Ji Won Han, et al.
Published: (2021) -
Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
by: Ahlim Lee, et al.
Published: (2022) -
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
by: Albert Jang, et al.
Published: (2023) -
Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)